New partnership may pave the way for first Novo Nordisk stem cell treatment

The new partnership with Japanese company Heartseed may give Novo Nordisk the chance to launch a stem cell therapy earlier than expected.

Jacob Sten Petersen, corporate vice president of stem cell research and development at Novo Nordisk | Photo: Novo Nordisk/PR

Novo Nordisk is expanding its interest in stem cells to a new disease area through the new agreement with Heartseed.

The collaboration revolves around HS-001, a cardiovascular disease treatment candidate which will be tested in patients with heart failure caused by ischemic heart disease in the second half of 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs